Major Shareholder Announcement
October 04, 2024 13:55 ET
|
Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
September 26, 2024 15:17 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 23,954 restricted stock units and 13,915 warrants to employees...
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
September 15, 2024 08:45 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
September 10, 2024 16:06 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The...
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024 12:26 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; August 26, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will...
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
August 19, 2024 14:00 ET
|
Genmab A/S
Company Announcement TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma...
Genmab Announces Changes to its Executive Committee
August 16, 2024 09:00 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology OfficerBrad Bailey appointed as Executive Vice President and Chief...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
August 13, 2024 14:53 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
August 13, 2024 14:51 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,193 shares as a consequence of the exercise of employee warrants. The...
Genmab Announces Financial Results for the First Half of 2024
August 08, 2024 11:03 ET
|
Genmab A/S
August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights Completed acquisition of ProfoundBio Inc (ProfoundBio), granting Genmab worldwide rights to...